MAY 31, 2015 11:46 AM PDT

Chemoresistance Characteristics in HSC

Genetic mechanisms of resistance to chemotherapy in the most common and the most lethal form of ovarian cancer may provide clues as to why that cancer initially succumbs to the drugs and then resists them, according to a large study published in Nature and reported by Catharine Paddock, Ph.D., in Medical News Today on May 29 (http://www.medicalnewstoday.com/articles/294575.php).
Some deadly cancer cells appear to be controlled by chemotherapy, but then they fail to respond to drugs.
According to Russell Vang, M.D., Ie-Ming Shih, M.D., Ph.D., and Robert J. Kurman, M.D., writing in Advanced Anatomical Pathology and published on the National Center for Biotechnology Information website, high-grade serous carcinomas are characterized by certain mutations and genetic instability, may originate from intraepithelial carcinoma in the fallopian tube and develop rapidly. They initially respond to chemotherapy better than low-grade serous carcinomas (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2745605/).

The study of the genetic mechanisms of chemoresistance in high-grade serous ovarian carcinoma (HSC), the most malignant form of ovarian cancer, was enabled by the Australian Ovarian Cancer Study (AOCS), which collects ovarian cancer tissue samples from donors. Funding came from the National Health and Medical Research Council (Australia), Worldwide Cancer Research, Cancer Australia, Ovarian Cancer Action (UK) and Ovarian Cancer Australia.

Resistance to chemotherapy is a major factor in HSC, which accounts for 70 percent of all ovarian cancers, 60 percent of deaths related to the disease and 80,000 deaths annually worldwide. According to the recent study's co-senior author and professor David Bowtell of the Peter MacCallum Cancer Centre in Melbourne, Australia, "For decades clinicians around the world have watched HSCs shrink under attack from chemotherapy, before returning aggressively months or years later."

To find out how and why the aggressive cancer changes from initially being vulnerable, to eventually becoming highly resistant to chemotherapy, Bowtell and his colleagues sequenced the genomes of 114 HSC samples from 92 patients. They collected samples at various stages in disease progression - some at diagnosis, some following successful and unsuccessful treatment, and others immediately after death, creating the first genetic map of how HSC evolves in response to chemotherapy.

Prof. Bowtell described four genetic changes in the cancer cells: "In two of the mechanisms, cancer cells find a way of restoring their ability to repair damaged DNA and thereby resist the effects of chemotherapy; in another, cancer cells 'hijack' a genetic switch that enables them to pump chemotherapy drugs out of harm's way. A further mechanism sees the molecular structure of the cancer tissue shift and reshape, such that sheets of 'scar tissue' appear to block chemotherapy from reaching its target."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
AUG 07, 2018
Cancer
AUG 07, 2018
Renal Cell Carcinoma and Myelodysplastic Syndrome Show Epigenetic Association
DNA methylation patterns in renal cell carcinoma (RCC) have a strong association with myelodysplastic syndrome DNA hypermethylation later in life....
SEP 15, 2018
Clinical & Molecular DX
SEP 15, 2018
Cancer & Anoikis: A Match Not Made in Heaven
Anoikis have always been intimately entwined with cancer, henceforth the quest to seek how they came to be as such....
NOV 05, 2018
Cell & Molecular Biology
NOV 05, 2018
Using Imaging to Understand Cancer Growth
Most types of cells in our body go through a critical renewal process in which cells divide into two new ones. But it can get out of control as well....
NOV 12, 2018
Cancer
NOV 12, 2018
Targeted radiation therapy may provide new hope to children with difficult-to-treat liver cancer
Primary malignant liver tumors are rare in children with an occurrence rate of 1-2% of all childhood cancers. Radical surgical resection of the liver which means the removal of part of the li...
DEC 03, 2018
Cancer
DEC 03, 2018
Using bubbly nano-particles for chemotherapy delivery
We have all heard about the harsh side effects of chemotherapy that could be so difficult leading to stopping treatment. The reason behind those side effects is that chemotherapy drugs do tar...
DEC 05, 2018
Immunology
DEC 05, 2018
Combo-Kick to Battle Lymphoma
Combination immunotherapy has provided remission for patients suffering from Hodgkin's Lymphoma...
Loading Comments...